Latest News - Bristol-Myers Squibb
Top Corporates Hub
Bristol-Myers Squibb
Blue Matter Expands Capabilities in Healthcare Policy Support for Life Sciences Led by Partner, Milena Sullivan
09.06.2026 13:01
NEW YORK, June 09, 2026--Blue Matter today announced the launch of an expanded policy capability to support biopharma clients, led by Milena Sullivan, a Partner who joined the firm in December 2025.
Inside Bristol Myers’ AI-powered procurement overhaul
09.06.2026 06:00
The pharmaceutical giant cut procurement timelines from months to weeks while challenging conventional wisdom on AI data readiness.
How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen
05.06.2026 04:39
Earlier this week, the European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with AVD chemotherapy as the first immunotherapy-based frontline regimen for adults and adolescents with previously untreated Stage III or IV classical Hodgkin lymphoma in the EU. This decision expands Opdivo’s reach into earlier-stage treatment of a cancer that is especially common in adolescents and young adults, potentially broadening Bristol Myers Squibb’s hematology-oncology...
Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation
04.06.2026 10:11
Bristol Myers Squibb (NYSE:BMY) received European Commission approval for Opdivo plus AVD as the first immunotherapy-based first-line regimen for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents. At ASCO 2026, the company reported late-breaking Phase 3 results for mezigdomide in relapsed or refractory multiple myeloma, with a 52% reduction in disease progression or death. Izalontamab brengitecan Phase 3 data at the same meeting indicated meaningful survival...
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
03.06.2026 08:05
Whichever one you choose, you'll need patience before you can see solid returns.
BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos
02.06.2026 16:57
Bristol Myers secured EU approval for Opdivo plus AVD in newly diagnosed advanced cHL and advanced Camzyos' label expansion review.
Assessing Bristol Myers Squibb (BMY) Valuation As Shares Track Mixed Returns And Earnings Outlook
02.06.2026 12:05
Bristol-Myers Squibb (BMY) continues to draw attention as investors weigh its current share price of US$54.95 against recent share performance and fundamentals, including revenue of US$48.5b and net income of US$7.3b. See our latest analysis for Bristol-Myers Squibb. The recent 7 day share price return fell 7.58% and the 90 day share price return is down 10.24%, yet the 1 year total shareholder return of 18.25% points to momentum that has been positive over a longer window. If you are...
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
02.06.2026 12:00
REDMOND, Wash. & PRINCETON, N.J., June 02, 2026--Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival....
Bristol Myers Squibb: This Pullback Is A Gift For Long-Term Investors
02.06.2026 10:59
Buy Bristol Myers Squibb (BMY) on the dip: low 8.7x forward P/E, 4.6% yield, 9% sales growth and key H2 2026 readouts.
C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout
02.06.2026 10:58
I initiate C4 Therapeutics (CCCC) with a Buy rating, driven by robust progress of its next-gen CELMoD cemsidomide in relapsed/refractory multiple myeloma.
SystImmune And Bristol Myers Squibb Announce Sichuan Biokin Reports Results From Prespecified Interim Analyses Of Two Phase 3 Studies Evaluating Izalontamab Brengitecan
02.06.2026 08:04
Interim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented at ASCO® 2026SystImmune and Bristol Myers Squibb's potent dual-targeted EGFRxHER3 bispecific antibody-drug conjugate
Bristol Myers' Growth Portfolio Just Overtook The Legacy One
02.06.2026 04:23
Bristol Myers Squibb (BMY) looks undervalued: 4 near-term pipeline catalysts and DCF imply ~20% upside, plus 4.35% yield. Read here for more details.
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks
02.06.2026 03:35
Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.
Bristol-Myers Squibb (BMY) Partners with Anthropic
29.05.2026 05:37
Bristol-Myers Squibb Company (NYSE:BMY) is one of the 12 Most Undervalued Stocks to Invest In. On May 20, 2026, Bristol-Myers Squibb Company (NYSE:BMY) announced a strategic agreement with Anthropic to deploy Claude across its research, clinical development, manufacturing, commercial, and corporate functions. Bristol Myers Squibb said the collaboration moves its AI use beyond conversational tools […]
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?
28.05.2026 14:49
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
28.05.2026 12:03
MOUNTAIN VIEW, Calif., May 28, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026.
Bristol-Myers Squibb Is Quietly Building Its Next Growth Cycle
27.05.2026 10:09
Bristol-Myers Squibb Company targets upper-end 2026 guidance on Breyanzi, Camzyos & Reblozyl growth; ASCO 2026 catalysts ahead. Click for this BMY update.
Tempus AI, Inc. (TEM) and Bristol Myers Announce a Strategic Partnership
23.05.2026 04:49
Tempus AI, Inc. (NASDAQ:TEM) is one of the 10 Best ARK Stocks to Buy Right Now. On May 14, Tempus AI, Inc. (NASDAQ:TEM) announced a collaboration with Bristol Myers Squibb to maximize clinical trials. The partnership will use multimodal data and AI to improve trial design and boost the probability of technical and regulatory success […]
Vanguard’s VIG Quietly Returned 247% While Investors Chased Higher Yields
22.05.2026 16:14
Retirees evaluating dividend funds tend to anchor on current yield, which is exactly why Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) often gets overlooked. The fund pays a distribution yield of roughly 1.6%, which looks unimpressive next to higher-yielding alternatives. Morningstar analysts have repeatedly flagged VIG as a quiet winner for retirees precisely because of that misread. ... Vanguard’s VIG Quietly Returned 247% While Investors Chased Higher Yields
1 Profitable Stock to Keep an Eye On and 2 We Brush Off
22.05.2026 16:04
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.